LOS ANGELES - eTradeWire -- A team of researchers from the University of California, Los Angeles (UCLA) has developed a new paper-based serological test that can rapidly and accurately monitor changes in immunity against SARS-CoV-2, the virus responsible for COVID-19. This innovative technology promises to revolutionize how we assess and track immunity in individuals, providing critical data to inform public health decisions.

The study, led by Professors Aydogan Ozcan and Dino Di Carlo, presents a paper-based multiplexed vertical flow assay (xVFA) that detects levels of IgG and IgM antibodies against five structural proteins of SARS-CoV-2. The test uses only a small volume of serum and delivers results in under 20 minutes, offering a significant advancement over existing methods.

The xVFA platform can assess immunity status with an accuracy of 89.5%. This is achieved by detecting specific antibody responses using a mobile phone-based reader and a neural network-based serodiagnostic algorithm. Unlike traditional serological assays that require expensive and bulky equipment, the xVFA is both affordable and portable. This makes it ideal for point-of-care use, especially in resource-limited settings where quick and reliable testing is crucial. The test simultaneously measures IgG and IgM antibodies against multiple SARS-CoV-2 proteins, providing a comprehensive profile of an individual's immunity. This capability is essential for distinguishing between antibodies generated by vaccination and those from past infections.

More on eTradeWire News

• Harris Cleaning Services is the Ultimate Post-Construction Commercial Cleaning Service
• Immokalee Fair Housing Alliance awarded Non-Profit Impact of the Year
• K4Connect Partners with Thryve Health to Personalize Wellness Through Wearable Device Integration
• Global Learning Charter Public School to Hold Annual Global Gala Scholarship Fundraiser on May 9th
• PAG Law Represents Expeditionary Engineering Inc. in Strategic Acquisition by Ultra Intelligence & Communications

The xVFA is a paper-based platform that incorporates several layers to create a vertical flow network, enabling capillary action to transport the serum sample through different testing regions. The assay panel contains 17 spots, including duplicates of the five SARS-CoV-2 proteins and control spots.

Upon applying a serum sample, the test detects the presence of antibodies that bind to these proteins. A custom-designed mobile phone-based optical reader captures images of the paper-based sensor, and the collected data are processed by a deep learning algorithm to classify the immunity status of the individual into one of three categories: protected, unprotected, or infected.

The development of this rapid and reliable serological test has significant implications for public health by empowering timely vaccination decisions, serving surveillance and epidemiology and offering accessibility to diagnostic technology in resource-poor areas.

More on eTradeWire News

• Ketcham Racing Hosts Spring Car Show
• YourEggs Egg Donation Bank Launches Pride Eggs: A New Division Dedicated to Celebrating and Supporting LGBTQ+ Families
• Indie Game Publisher Joins Federal Lawsuit Challenging Trump Administration's Illegal Tariffs
• StablePayLabs Introduces Advanced Micropayment Solution with Blockchain, DAOs, and Stablecoins
• Day On The Farm: Santa Ynez Valley Historical Museum Tour

The UCLA team is committed to further enhancing the capabilities of the xVFA. Future research will focus on expanding the test to include other pathogens and adapting the platform for use with different types of vaccines. The team also plans to refine the machine learning algorithm to improve accuracy and extend the technology's applications to broader public health monitoring needs.

This research was supported by the U.S. National Science Foundation.

Original publication: https://pubs.acs.org/doi/10.1021/acsnano.4c02434